The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DBVT | +334.38% | -44.48% | -11.1% | -95% |
| S&P | +14.49% | +91.09% | +13.83% | +251% |
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
"The New England Journal of Medicine" reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers.
The company can now move forward with a late-stage study of its lead pipeline candidate.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$4.28M | -37.4% |
| Market Cap | $273.53M | 306.2% |
| Market Cap / Employee | $2.51M | 0.0% |
| Employees | 109 | 4.8% |
| Net Income | -$33.02M | -8.1% |
| EBITDA | -$32.61M | -14.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $69.84M | 50.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $6.69M | -4.9% |
| Short Term Debt | $9.31M | 17.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -123.18% | -50.9% |
| Return On Invested Capital | -120.74% | -51.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$32.48M | -42.1% |
| Operating Free Cash Flow | -$32.36M | -44.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.10 | 2.43 | 65.44 | 3.17 | 154.54% |
| Price to Tangible Book Value | 1.10 | 2.43 | 66.11 | 3.17 | -25.49% |
| Enterprise Value to EBITDA | -1.80 | -5.63 | -3.15 | -5.49 | 439.41% |
| Return on Equity | -135.8% | -198.3% | -148.7% | -234.6% | 127.33% |
| Total Debt | $15.09M | $12.35M | $14.59M | $16.00M | 6.77% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
